The insider buy is symbolic rather than material given its small size. Monitor for further insider accumulation or clinical catalysts around the Phase 2a trial for foralumab in non-active secondary progressive MS. No immediate price catalyst expected from this filing alone.
Price Chart
Executive Summary
Executive Chairman and Founder Gabriele Cerrone purchased 42,357 common shares at $0.99 per share, increasing his total holdings to 44,814,587 shares (34.93% of issued capital). The buy is small in absolute dollar terms (~$42k) relative to his existing stake and market cap ($127M), but may signal alignment with shareholders.
Key Facts
- Executive Chairman Gabriele Cerrone bought 42,357 shares at $0.99/share via Panetta Partners Ltd
- Post-purchase holdings: 44,814,587 shares = 34.93% of issued capital
- Total purchase value approximately $41,933
- Filing is a voluntary press release disclosure, not a Form 4
Financial Impact
Insider purchase of ~$42k, negligible relative to $127M market cap
Risk Factors
- Pre-revenue clinical-stage biotech with no approved products
- Dependence on foralumab clinical trial outcomes (Phase 2a NCT06292923)
- Potential future dilution common for development-stage companies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-080178 |
| Document: ea029884501ex99-1.htm | 0001213900-26-080178 |
| Document: 0001213900-26-080178-index-headers.html | 0001213900-26-080178 |
| Document: 0001213900-26-080178-index.html | 0001213900-26-080178 |
| Document: 0001213900-26-080178.txt | 0001213900-26-080178 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $1.01 | awaiting T+20 | — | $0.8907 (−11.81%) |
Oct 16, 2026 9d ago | 6-K | $1.01 | awaiting T+20 | — | $0.8907 (+11.81%) |
Oct 16, 2026 10d ago | 6-K | $1.05 | awaiting T+20 | — | $0.8907 (−15.17%) |
Sep 30, 2026 26d ago | 6-K | $1.11 | awaiting T+20 | — | $0.8907 (−19.76%) |
Sep 28, 2026 28d ago | 6-K | $0.9800 | awaiting T+20 | — | $0.8907 (−9.11%) |
Sep 21, 2026 5w ago | 6-K | $0.9046 $1.01 | ▲ +11.65% | ▲ +12.56% | $0.8907 (−1.54%) |
Sep 17, 2026 5w ago | 6-K | $0.9700 $1.05 | ▲ +8.25% | ▲ +7.04% | $0.8907 (−8.18%) |
Sep 17, 2026 5w ago | Press Release | $0.9700 $1.05 | ▲ +8.25% | ▲ +7.04% | $0.8907 (−8.18%) |
Aug 24, 2026 9w ago | 6-K | $1.15 $0.8899 | ▼ −22.62% | ▼ −23.93% | $0.8907 (−22.55%) |
Aug 6, 2026 11w ago | 6-K | $0.9700 $0.9745 | ▲ +0.46% | ▼ −0.14% | $0.8907 (−8.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers